DOAC
E861729
DOAC (direct oral anticoagulant) is a class of blood-thinning medications that directly inhibit specific clotting factors to prevent and treat thromboembolic events.
All labels observed (1)
| Label | Occurrences |
|---|---|
| DOAC canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10401918 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: DOAC Context triple: [dabigatran, hasPharmacologicClass, DOAC]
-
A.
dabigatran
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
-
B.
apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
C.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
D.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
E.
warfarin
Warfarin is a long-established oral anticoagulant used to prevent and treat blood clots, requiring regular blood monitoring and dose adjustments due to its narrow therapeutic range and numerous drug and food interactions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: DOAC Target entity description: DOAC (direct oral anticoagulant) is a class of blood-thinning medications that directly inhibit specific clotting factors to prevent and treat thromboembolic events.
-
A.
dabigatran
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
-
B.
apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
C.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
D.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
E.
warfarin
Warfarin is a long-established oral anticoagulant used to prevent and treat blood clots, requiring regular blood monitoring and dose adjustments due to its narrow therapeutic range and numerous drug and food interactions.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anticoagulant drug
ⓘ
class of medication ⓘ |
| abbreviationOf | direct oral anticoagulant ⓘ |
| alternativeTo | warfarin ⓘ |
| benefitComparedToWarfarin |
fewer drug interactions (agent-dependent)
ⓘ
fewer food interactions ⓘ fixed dosing ⓘ no routine INR monitoring ⓘ |
| clinicalGuidelineUse | recommended first-line for non-valvular atrial fibrillation in many guidelines ⓘ |
| comparedTo | vitamin K antagonist ⓘ |
| contraindicatedIn |
mechanical heart valves
ⓘ
severe renal impairment ⓘ |
| drugInteractionWith |
strong CYP3A4 inhibitors
ⓘ
strong P-glycoprotein inhibitors ⓘ |
| elimination | renal excretion (varies by agent) ⓘ |
| fullName | direct oral anticoagulant ⓘ |
| hasAdverseEffect |
bleeding
ⓘ
gastrointestinal bleeding ⓘ intracranial hemorrhage ⓘ |
| hasMechanismOfAction | direct inhibition of specific coagulation factors ⓘ |
| hasPharmacologicalEffect | anticoagulation ⓘ |
| hasReversalAgent |
andexanet alfa
ⓘ
idarucizumab ⓘ |
| hasReversalStrategy | prothrombin complex concentrate ⓘ |
| hasSubclass |
direct thrombin inhibitor
ⓘ
factor Xa inhibitor ⓘ |
| includesDrug |
apixaban
ⓘ
betrixaban ⓘ dabigatran ⓘ edoxaban ⓘ rivaroxaban ⓘ
linked to:
Xarelto
|
| metabolism | hepatic metabolism (varies by agent) ⓘ |
| monitoringRequirement | no routine coagulation monitoring required in most patients ⓘ |
| onsetOfAction | rapid ⓘ |
| requiresDoseAdjustmentIn |
hepatic impairment
ⓘ
renal impairment ⓘ |
| riskComparedToWarfarin |
higher cost
ⓘ
limited use in severe renal dysfunction ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
coagulation factor IIa
ⓘ
coagulation factor Xa ⓘ |
| usedFor |
prevention of recurrent deep vein thrombosis
ⓘ
prevention of recurrent pulmonary embolism ⓘ prevention of stroke in non-valvular atrial fibrillation ⓘ prevention of thromboembolic events ⓘ treatment of deep vein thrombosis ⓘ treatment of pulmonary embolism ⓘ treatment of thromboembolic events ⓘ venous thromboembolism prophylaxis after orthopedic surgery ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: DOAC Description of subject: DOAC (direct oral anticoagulant) is a class of blood-thinning medications that directly inhibit specific clotting factors to prevent and treat thromboembolic events.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.